An interventional study of Penile vibrator in Erectile Dysfunction Following Radical Prostatectomy and Incontinence, sponsored by Herlev and Gentofte Hospital. Recruiting at 1 site in Denmark. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-12.
Sponsored by Herlev and Gentofte Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Erectile Dysfunction with a site in Denmark — 2 open to participants now, 3 under way, none of them phase 3. Erectile Dysfunction · Denmark.
Among the 18 studies in Erectile Dysfunction with a site in Denmark, this one is the 4th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2024, is one of 9 with no phase, and was the 16th registered.
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
Browse Erectile Dysfunction studies →2 of the 18 studies in Erectile Dysfunction with a site in Denmark are open now. Recruiting first, the newest first:
Herlev and Gentofte Hospital · Sites in Denmark
Ages 40–75 · Men only
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Median enrollment 90 across the 14 interventional studies, 298 across the 4 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 18 have an industry lead sponsor. The 10 most frequent:
Herlev and Gentofte Hospital is the lead sponsor of 75 studies on the registry; 25 are open to participants now.
Herlev and Gentofte Hospital has 5 studies filed under Erectile Dysfunction — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Erectile Dysfunction with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To investigate if post-operative penile vibration stimulation kan be used to reduce or prevent sexual dysfunction and urinary incontinence after radical prostatectomy. This will be done in a randomized, controlled, non-blinded study. Men that undergo nerve preserving surgery for prostate cancer is allocated into an intervention group and a control group. A total of 100 men will be included for a power of 80%. The intervention group will be instructed to use the "Ferticare 2.0" vibrator for at least five minutes a day with an amplitude of 1 mm and frequency of 90 Hz (these settings were found in a pilot study) for a total of 9 months.
Both groups will do the standard pelvic floor training program and both groups will be offered regular phosphodiesterase-5-inhibitor treatment. Before surgery, 3, 6 and 10 months after the patients will have to fill out four different questionnaires regarding sexual and urinary function, including IIEF-EF, EHS, "neglected side effects" and ICIQ-SF. (10 months is due to a wash-out period of 1 month after the intervention).
The collected data will be analysed and the primary goal is to see if there is a significant difference in average spontaneous IIEF-EF score in the two groups 10 months after the surgery.
Hypothesis The study's hypothesis is that vibration therapy, using the stimulation parameters found in the pilot study, will have a beneficial effect on erectile function, orgasm disturbances, penile shortening, and urinary incontinence, both generally and in connection with sexual activity.
Methods The study is conducted as a randomized, controlled non-blinded study. Men undergoing a nerve-sparing operation for prostate cancer are divided into two groups. A total of 100 men will be included in the study. In case a surgery cannot be performed with nerve preservation or if a participant experiences a recurrence of their prostate cancer requiring additional treatment, the participant will be withdrawn from the study.
Randomization and Treatment Overall, we will investigate the effect of vibration stimulation on erectile function, orgasm disturbances, penile shortening, and urinary incontinence, both generally and in connection with sexual activity. In accordance with the hypotheses, this study will offer vibration therapy for a longer duration than before. Both the vibration group and the control group will be offered fixed post-operative treatment with phosphodiesterase-5-inhibitors as per the standard protocol. Participants will be randomized into the two groups through drawing lots for either vibration or no vibration. Randomization will be done using block randomization via a computer-generated list. The "Ferticare 2.0" vibrator (produced by the company Reflexonic LLC, Leesburg VA, USA) will be used in the study, which is a modernized version of the previously used vibrator and is sold as a sexual aid in Denmark. It is safety-approved with European CE marking as a "household appliance" and is sold as a sexual aid in Denmark. Men in the vibration group will be instructed on the stimulation before their prostate surgery. Subsequently, participants will be able to perform the vibration therapy themselves at home. In both groups, participants must undergo a standard pelvic floor training program, and both groups will be offered fixed PDE-5 inhibitor treatment in the form of daily tadalafil, 5 mg, as the standard treatment for erectile difficulties after the operation. In the vibration group, daily stimulation will be directed towards the frenulum for a minimum of 5 minutes, with an amplitude of 1 mm and a frequency of 90 Hz, as found in the pilot study. Participants will start getting used to the vibration 1-4 weeks before the surgery and resume it within 14 days after the operation. The daily stimulation will continue for a period of 9 months, along with the standard treatment. After these 9 months, men in both groups will stop taking tadalafil during a 4-week wash-out period, after which their spontaneous sexual function will be evaluated. This is necessary due to the well-known positive effect of the medication. In comparison to the standard treatment in the department, offering vibration to half of the participants is an addition. Regarding pelvic floor training and medication for erectile difficulties for all study participants, the current standard is to offer these to all men who have undergone nerve-sparing radical prostatectomy. This will proceed as usual, and the only deviation from usual practice is ensuring that the medication offer is consistent for all participants. The mentioned 4-week period without tablet treatment (wash-out) is necessary to assess spontaneous erections. This is a deviation from the normal standard, as such a wash-out is not conducted for patients who do not participate in research, but it will not affect the actual erectile function of the participants in either group.
Data Collection
Standard investigations related to prostate cancer will be conducted according to normal guidelines, with the registration of:
Since potential participants are screened and informed about the project during their visits to the outpatient clinic (see the section on Recruitment of Study Participants and Informed Consent), there is no need to obtain information from the patient's medical records before consent is given. At this stage, the research team only receives the name, social security number, and contact information for patients who have expressed interest in the project.
Additional examinations are carried out before the surgery and at follow-ups at 3 months, 6 months, and 10 months (equivalent to the end of the wash-out period) after the surgery, with the registration of the following for all participants in both the vibration group and the control group:
Before the surgery and at follow-ups:
Additional registrations at follow-ups:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The group randomized to use the vibrator for 9 months
Device: Penile vibrator
Usual standard treatment
In addition to standard treatment with PDE5-inhibitors the intervention is daily stimulation for five minutes with the vibrator for 9 months
Erectile function
The erectile function compared to controls measured by IIEF-EF
Time frame: 10 months
ICIQ-UI-SF: The International Consultation on Incontinence Questionnaire - Urinary Incontinence - short form
Difference in ICIQ-SF score between the two groups after 3, 6 and 10 months. The score is from 0-21. The higher the score the more incontinent. A score of 0 is no urinary incontinence.
Time frame: 10 months
IIEF-EF score (The International Index of Erectile Function - Erectile Function)
Difference in IIEF-EF score between the two groups after 3, 6 and 10 months. The minimum score is 0 and the maximum score is 30. The higher the score the better erectile function.
Time frame: 10 months
Diaper weighing test
Difference in 24 hour diaper weighing test between the two groups after 3, 6 and 10 months
Time frame: 10 months
IIEF-EF (The International Index of Erectile Function - Erectile Function) over 25
The percentage of patients who gain a post-operative spontaneous IIEF-EF score of at least 25. The minimum score is 0 and the maximum score is 30. The higher the score the better erectile function.
Time frame: 10 months
EHS (Erection Hardness Scale)
The percentage of patients who gain a post-operative spontaneous EHS of at least 3. The scale is from 0-4. 0 is no erection, the higher the score the better erection.
Time frame: 10 months
Neglected sexual side effects
The presence of orgasm disturbances, penile shortening and urinary incontinence in relation to sexual activity.
Time frame: 10 months
Plan to share: Yes — Available upon request. Subject to approval from the Danish Data Protection Agency.
Supporting information: Study protocol, Statistical analysis plan
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for Mar 2026, 25 months after the start.
Of 115 non-industry interventional studies with no phase under Erectile Dysfunction, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 25 months is below that.
Counting every sponsor, half of 137 studies reached it within 32 months; a quarter within 14 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Herlev and Gentofte Hospital